N ext-generation sequencing (NGS), also known as massively parallel sequencing (MPS) technology, is transforming the field of genomics, playing a central role in the movement toward personalized medicine. In contrast to Sanger sequencing, which determines the specific base pairs (bp) present in single long-range DNA molecules, NGS consists of numerous rounds of repeated sequencing of short genomic fragments (approx. 150 bp) performed on multiple samples simultaneously. Computational reconstruction of each genome is then performed, and the sequence is compared against a "reference" genome. This approach drastically decreases the reagent cost of sequencing the entire human genome and the challenge becomes the downstream computational analysis and interpretation. As with all emerging technologies, understanding the method and limitations will be important to optimize clinical application; for transfusion medicine, being open to new approaches with potential to improve patient care and streamline pretransfusion testing will be critical for its adoption.
NGS OR MPS APPROACHES
The inherent "personalized" nature of selecting the best blood product for each patient, along with the breadth of genomic information potentially relevant for transfusion therapy (e.g., red blood cells [RBCs] , platelets [PLTs] , neutrophil antigens, and HLA) and the documented clinical value, make transfusion medicine an ideal field for the use of NGS or MPS data. A number of publications over the past 6 years have provided sound proof-of-principle examples of the application of targeted (sequencing specific genes), exome (sequencing the coding regions only), or whole genome (sequencing both coding and noncoding regions) NGS to determine the extended RBC, PLT, RH, or HLA profiles of patients or donors.
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NGS OR MPS IN THE REFERENCE LABORATORY
In this issue of TRANSFUSION, Schoeman and colleagues 9 describe the first example of the use of a NGS or MPS commercial panel, which targets diseaseassociated genes as well as the exon regions of 41 genes and two transcription factors associated with RBC antigens, as part of the reference laboratory workup to resolve complex cases. As Schoeman and coworkers 9 illustrate, the advantages of MPS or NGS include the capability of identifying rare and novel blood group variants that would otherwise be unrecognized with current DNA-array platforms that target common blood group polymorphisms. Indeed, although Sanger sequencing is used in some complex reference laboratories when the workup suggests the presence of a new variant in a specific blood group system, a major strength lies in the fact that MPS or NGS enables analysis of all genes encoding blood group antigens simultaneously. MPS or NGS also allows copy number analysis and, as demonstrated in the report, the detection of chimeric samples. MPS or NGS thus emerges as a new tool for immunohematology reference laboratories to resolve or confirm discrepant or inconclusive results, particularly when the antibody specificity is uncertain or, importantly, when transfused RBC survival is compromised in the absence of detectable antibody.
CHALLENGES Access and cost
Along with the potential strengths of this approach come a number of challenges. These issues include access to MPS or NGS equipment, training of personnel in library preparation, and the need for bioinformatics expertise for data interpretation. Processing and analysis takes several days. Cost is a consideration, with the latest NHGRI data from July 2017 indicating a cost of $1121 to sequence an entire human genome. 9 Exome sequencing, which targets only the coding region (exons), reduces cost and produces a smaller and more manageable volume of bioinformatics data, but as demonstrated by Schoeman and coworkers, 10 the commercial exome library preparation they used did not target exons of all blood groups.
Polymorphisms of unknown significance
Novel genetic changes of unknown significance will be encountered and will require evaluation. This task will not be simple, and current computational prediction algorithms, such as SIFT and Polyphen utilized by Schoeman and colleagues, 10 antigens are defined as polymorphisms associated with production of a specific antibody, and this direct relationship must be proven. Expression studies, and/or family studies, including resequencing, will be needed to substantiate novel findings and to confirm antibody/ antigen associations. Indeed, the authors found novel variants in blood group genes of possible significance in their samples. The presence of novel changes in blood group genes has been a consistent finding in every study employing NGS or MPS for blood group genotyping. Worldwide studies confirm that we have yet to uncover the full range of human genomic variation, particularly in the African population who are also frequently hemoglobinopathy carriers. Thus, we must be prepared to characterize, classify, and catalog clinically relevant as well as benign blood group variation.
Reference genome and interpretation
NGS or MPS data require a robust bioinformatics analysis pipeline, tested and optimized for transfusion medicine that also incorporates RBC antigen prediction and HPA, HLA, and possibly relevant white blood cell antigens. Schoeman and coworkers 10 provide a detailed description of the data filters used in their study (i.e., quality, alternate allele percent and coverage thresholds, strand bias detection), but work remains to be performed to determine if parameter selection and threshold values need to be optimized for blood group genes or for specific data sets. Blood group allele tables are referenced according to location in cDNA, but for NGS analysis the polymorphisms must be converted to genomic coordinates. Without computerized algorithms capable of interpreting relevant information directly from NGS or MPS files, translation will be laborious and time-intensive and can only be performed by bioinformatics and blood group genetics subject matter experts. Establishing a standard human reference genome to align NGS or MPS data is one of the tasks ahead, since there are instances where the current assemblies do not reflect the most common blood group genotype in the population. Some blood group genes in the reference genome have been artificially constructed from different source sequences. Equally important is to resolve any blood group allele table cDNA discrepancies and to establish a central, curated electronic database with a process to streamline reporting and revision.
Data management
The magnitude of NGS or MPS data files vary in size depending on the degree of coverage and the experimental design (whole genome vs. exome vs. a targeted gene panel), but can occupy at least tens of gigabytes per sample. This volume in turn brings all the nuances and challenges associated with the field of "big data science": data security, data storage, data provenance, metadata and data reusability standards, and need for a robust data management program. The nature and scope of informatic and computational resources required by NGS or MPS are distinct from those currently available in transfusion services and blood centers, and they will likely require focused interdisciplinary design and implementation efforts. Use of a platform that captures disease-related genomic sequences not relevant for transfusion medicine along with blood groups, as used by Schoeman and coworkers, 10 bring considerations regarding incidental and potentially actionable health findings from both an ethical and data security perspective.
PERSPECTIVES
An individual need only be sequenced once in his or her lifetime (possibly barring transplantation or malignancy), and this data will be "read" often. Thus, to fully harness the potential of NGS or MPS cost-effectively in the clinical setting, a system is required to securely and reliably share data across different clinical care settings, effectively extracting as much actionable data, relevant to the situation at hand, as possible from a single sequencing effort.
One can envision the hospital blood bank (and associated reference laboratory) as part of the pipeline to mine existing NGS or MPS data for transfusion medicine. Knowing which antigens the patient lacks creating risk for sensitization would streamline pretransfusion testing (number of rule-outs required) and enable informed decision making for selection of blood products. Existing sequence information on blood donors would also be useful, but access might possibly require a unique approach and pipeline if not performed by the donor center. Efforts to create an algorithm to directly interpret data from NGS or MPS "in the cloud" and to generate a report that includes the extended profile report are under way. 1 Although this approach requires further development and validation, access to existing data with secondary analysis potentially avoids data storage and security challenges. As NGS or MPS becomes more widespread, we can expect a substantial increase in the rate of novel blood group variants detected, highlighting the need for a central, dynamic, and open system to share these findings with the rest of the community 11 and to determine the clinical relevance. The ISBT Working Party on Red Cell Immunogenetics and Blood Group Terminology is working to establish an electronic allele database and also working with the Locus Reference Genome to define blood group reference alleles to standardize interpretation in the field.
CONCLUSIONS
Many researchers have now shown that NGS or MPS can provide adequate coverage of the genes that determine blood group extended antigen typing in patients and donors. Schoeman and colleagues 10 describe the first example of the use of NGS or MPS as part of the routine reference laboratory workup. The strength of this approach lies in the ability to potentially detect the relevant polymorphisms including null alleles, novel mutations, and complex gene rearrangements in blood group genes simultaneously. The cost of performing NGS or MPS continues to decrease precipitously. HLA typing is rapidly moving to targeted NGS or MPS, motivated by commercial investment in that field. RBC and PLT typing does not have the same commercial interest and support; however, patient genome sequencing as part of clinical care will likely become more commonplace, and this information can be used for transfusion medicine decision making. Notably, secondary analysis of existing NGS or MPS data using automated analytic software algorithms designed for transfusion medicine 1 represents a cost-effective and practical use of genomic information that could streamline pretransfusion testing, improve transfusion safety, and transform the way blood products are provided to patients.
